Citrate As a Safe and Effective Alternative to Heparin for Catheter Locking: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2025 Mar 13

PMID 40078385

Authors

Binbin Lai

Weixing Huang

Hui Yu

Tingting Chen

Yimen Gao

Wei Wang

Hua Luo

Affiliations

Soon will be listed here.

Abstract

Background: Consensus on the use of citrate vs.heparin for catheter locking remains elusive, with ongoing controversy. This meta-analysis investigates the efficacy and safety of citrate lock solutions compared to heparin lock solutions in preventing catheter-related complications.

Methods: The review process was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Two independent reviewers conducted literature searches based on preferred reporting items from systematic reviews and meta-analyses. PubMed, EMBASE, Medline, and the Cochrane Library were searched for studies comparing citrate and heparin in patients with catheter. Catheter-related bloodstream infection (CRBSI), catheter-related infection (CRI), exit-site infection (ESI), and adverse events were analyzed.

Results: The meta-analysis included 17 randomized controlled trials (RCTs), encompassing 247,431 catheter-days, with 128,904 in the citrate group, and 118,527 in the heparin group. Citrate lock solutions significantly reduced the incidence of CRBSI compared to heparin (RR: 0.48, 95% CI: 0.31-0.73), particularly when combined with antibiotics or used at low concentrations. No significant differences were observed between the groups for CRI, ESI, catheter dysfunction, or local bleeding. Subgroup and sensitivity analyses addressed heterogeneity, confirming the robustness of the primary findings.

Conclusions: Citrate lock solutions effectively prevent CRBSI without increasing systemic coagulation dysfunction or bleeding risk. Citrate lock solutions are a safe and effective alternative to heparin, especially when combined with antibiotics.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024562511.

References

Luiz M, Scavone C, Tzanno C . The CLOCK trial, a double-blinded randomized controlled trial: Trisodium citrate 30% and minocycline 3 mg/mL plus EDTA 30 mg/mL are effective and safe for catheter patency maintenance among CKD 5D patients on hemodialysis. Hemodial Int. 2016; 21(2):294-304. DOI: 10.1111/hdi.12492. View

Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P . Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artif Organs. 1998; 22(11):945-7. DOI: 10.1046/j.1525-1594.1998.06268.x. View

Kumbar L, Yee J . Current Concepts in Hemodialysis Vascular Access Infections. Adv Chronic Kidney Dis. 2019; 26(1):16-22. DOI: 10.1053/j.ackd.2018.10.005. View

Shea B, Reeves B, Wells G, Thuku M, Hamel C, Moran J . AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358:j4008. PMC: 5833365. DOI: 10.1136/bmj.j4008. View

Betjes M, van Agteren M . Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant. 2004; 19(6):1546-51. DOI: 10.1093/ndt/gfh014. View

Lai N, Chaiyakunapruk N, Lai N, ORiordan E, Pau W, Saint S . Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults. Cochrane Database Syst Rev. 2016; 3:CD007878. PMC: 6517176. DOI: 10.1002/14651858.CD007878.pub3. View

Stucker F, Ponte B, Tataw J, Martin P, Wozniak H, Pugin J . Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care. 2015; 19:91. PMC: 4364313. DOI: 10.1186/s13054-015-0822-z. View

Huang H, Chang Q, Zhou Y, Liao L . Risk factors of central catheter bloodstream infections in intensive care units: A systematic review and meta-analysis. PLoS One. 2024; 19(4):e0296723. PMC: 11037535. DOI: 10.1371/journal.pone.0296723. View

Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S . Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am J Infect Control. 2004; 32(3):155-60. DOI: 10.1016/j.ajic.2003.05.007. View

10.

Boer W, Fivez T, Vander Laenen M, Bruckers L, Gron H, Schetz M . Citrate dose for continuous hemofiltration: effect on calcium and magnesium balance, parathormone and vitamin D status, a randomized controlled trial. BMC Nephrol. 2021; 22(1):409. PMC: 8665615. DOI: 10.1186/s12882-021-02598-2. View

11.

Solomon L, Cheesbrough J, Ebah L, Al-Sayed T, Heap M, Millband N . A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am J Kidney Dis. 2010; 55(6):1060-8. DOI: 10.1053/j.ajkd.2009.11.025. View

12.

Boulet N, Pensier J, Occean B, Peray P, Mimoz O, Rickard C . Central venous catheter-related infections: a systematic review, meta-analysis, trial sequential analysis and meta-regression comparing ultrasound guidance and landmark technique for insertion. Crit Care. 2024; 28(1):378. PMC: 11577744. DOI: 10.1186/s13054-024-05162-0. View

13.

Donlan R . Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clin Infect Dis. 2011; 52(8):1038-45. DOI: 10.1093/cid/cir077. View

14.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

15.

Chung P, Toh Y . Anti-biofilm agents: recent breakthrough against multi-drug resistant Staphylococcus aureus. Pathog Dis. 2014; 70(3):231-9. DOI: 10.1111/2049-632X.12141. View

16.

Bosma J, Siegert C, Peerbooms P, Weijmer M . Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial. Nephrol Dial Transplant. 2009; 25(4):1213-7. DOI: 10.1093/ndt/gfp651. View

17.

Allon M . Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis. 2004; 44(5):779-91. View

18.

Abdel Azim A, ElSaid T, El Said H, Hemida W, Zaghlool S, Ramadan A . A randomized controlled clinical trial of 4% sodium citrate versus heparin as locking solution for temporary dialysis catheters among hemodialysis patients . Clin Nephrol. 2018; 90(5):341-349. DOI: 10.5414/CN109162. View

19.

Moran J, Sun S, Khababa I, Pedan A, Doss S, Schiller B . A randomized trial comparing gentamicin/citrate and heparin locks for central venous catheters in maintenance hemodialysis patients. Am J Kidney Dis. 2011; 59(1):102-7. DOI: 10.1053/j.ajkd.2011.08.031. View

20.

MacRae J, Dojcinovic I, Djurdjev O, Jung B, Shalansky S, Levin A . Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol. 2008; 3(2):369-74. PMC: 2390935. DOI: 10.2215/CJN.01760407. View